Commentary : Combating COVID-19-associated mucormycosis with limited resources.
作者信息
Kim Usha, Kulkarni Pooja, Saini Pragya
机构信息
Department of Orbit, Oculoplasty, Ocular Oncology and Ocular Prosthesis, Aravind Eye Hospital and Post Graduate Institute of Ophthalmology, Madurai, Tamil Nadu, India.
出版信息
Indian J Ophthalmol. 2022 Jun;70(6):2169. doi: 10.4103/ijo.IJO_1250_22.
Abstract
摘要
相似文献
1
Commentary : Combating COVID-19-associated mucormycosis with limited resources.
Indian J Ophthalmol. 2022 Jun;70(6):2169. doi: 10.4103/ijo.IJO_1250_22.
2
Mucormycosis: The hidden and forgotten disease.
J Appl Microbiol. 2022 Jun;132(6):4042-4057. doi: 10.1111/jam.15487. Epub 2022 Feb 23.
3
Mucormycosis in COVID-19: The Indian scenario.
J Mycol Med. 2022 Aug;32(3):101275. doi: 10.1016/j.mycmed.2022.101275. Epub 2022 Mar 23.
4
The emergence of post-COVID-19 mucormycosis in India: Can we prevent it?
Indian J Ophthalmol. 2021 Jul;69(7):1645-1647. doi: 10.4103/ijo.IJO_1392_21.
5
Risks of mucormycosis in the current Covid-19 pandemic: a clinical challenge in both immunocompromised and immunocompetent patients.
Mol Biol Rep. 2022 Jun;49(6):4977-4988. doi: 10.1007/s11033-022-07160-3. Epub 2022 Feb 2.
6
Evaluation of Mucorales DNA load in cerebrospinal fluid in a patient with possible cerebral mucormycosis treated with intravenous liposomal amphotericin B.
Int J Infect Dis. 2014 Dec;29:200-2. doi: 10.1016/j.ijid.2014.10.019. Epub 2014 Nov 6.
7
Bilateral blindness in a young male of rhino-orbital-cerebral mucormycosis: A case report.
Indian J Ophthalmol. 2022 May;70(5):1822-1824. doi: 10.4103/ijo.IJO_3141_21.
8
Commentary: COVID-19-associated mucormycosis: The ongoing battle.
Indian J Ophthalmol. 2021 Dec;69(12):3683-3684. doi: 10.4103/ijo.IJO_2789_21.
9
Evaluation of hospital environment for presence of Mucorales during COVID-19-associated mucormycosis outbreak in India - a multi-centre study.
J Hosp Infect. 2022 Apr;122:173-179. doi: 10.1016/j.jhin.2022.01.016. Epub 2022 Feb 3.
10
A Case of Esophageal Mucormycosis.
Am J Gastroenterol. 2022 Feb 1;117(2):355. doi: 10.14309/ajg.0000000000001592.
引用本文的文献
1
Rhino-orbito-cerebral mucormycosis and its resurgence during COVID-19 pandemic: A review.
Indian J Ophthalmol. 2023 Jan;71(1):39-56. doi: 10.4103/ijo.IJO_1219_22.
本文引用的文献
1
Analysis of COVID-19-associated rhino-orbital-cerebral mucormycosis patients in a tertiary care center in Northern India.
Indian J Ophthalmol. 2022 Jun;70(6):2163-2168. doi: 10.4103/ijo.IJO_340_22.
2
Cumulative Mortality and Factors Associated With Outcomes of Mucormycosis After COVID-19 at a Multispecialty Tertiary Care Center in India.
JAMA Ophthalmol. 2022 Jan 1;140(1):66-72. doi: 10.1001/jamaophthalmol.2021.5201.
3
Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India.
Diabetes Metab Syndr. 2021 Jul-Aug;15(4):102146. doi: 10.1016/j.dsx.2021.05.019. Epub 2021 May 21.
4
Epidemiology, clinical profile, management, and outcome of COVID-19-associated rhino-orbital-cerebral mucormycosis in 2826 patients in India - Collaborative OPAI-IJO Study on Mucormycosis in COVID-19 (COSMIC), Report 1.
Indian J Ophthalmol. 2021 Jul;69(7):1670-1692. doi: 10.4103/ijo.IJO_1565_21.
5
Outcomes of a Modified Treatment Ladder Algorithm Using Retrobulbar Amphotericin B for Invasive Fungal Rhino-Orbital Sinusitis.
Am J Ophthalmol. 2022 May;237:299-309. doi: 10.1016/j.ajo.2021.05.025. Epub 2021 Jun 9.
Zotero 插件